Unknown

Dataset Information

0

Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan.


ABSTRACT:

Aims

Glutamic acid decarboxylase autoantibodies (GADAb) differentiate slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) from phenotypic type 2 diabetes, but many GADAb-positive patients with diabetes do not progress to insulin-requiring diabetes. To characterize GADAb-positive patients with adult-onset diabetes who do not require insulin therapy for >5 years (NIR-SPIDDM), we conducted a nationwide cross-sectional survey in Japan.

Methods

We collected 82 GADAb-positive patients who did not require insulin therapy for >5 years (NIR-SPIDDM) and compared them with 63 patients with insulin-requiring SPIDDM (IR-SPIDDM). Clinical and biochemical characteristics, HLA-DRB1-DQB1 haplotypes, and predictive markers for progression to insulin therapy were investigated.

Results

Compared with the IR-SPIDDM group, the NIR-SPIDDM patients showed later diabetes onset, higher body mass index, longer duration before diagnosis, and less frequent hyperglycemic symptoms at onset. In addition, C-peptide, LDL-cholesterol, and TG were significantly higher in the NIR-SPIDDM compared to IR-SPIDDM patients. The NIR-SPIDDM group had lower frequency of susceptible HLA-DRB1*04:05-DQB1*04:01 and a higher frequency of resistant HLA-DRB1*15:01-DQB1*06:02 haplotype compared to IR-SPIDDM. A multivariable analysis showed that age at diabetes onset (OR = 0.82), duration before diagnosis of GADAb-positive diabetes (OR = 0.82), higher GADAb level (?10.0 U/ml) (OR = 20.41), and fasting C-peptide at diagnosis (OR = 0.07) were independent predictive markers for progression to insulin-requiring diabetes. An ROC curve analysis showed that the optimal cut-off points for discriminating two groups was the GADAb level of 13.6 U/ml, age of diabetes onset of 47 years, duration before diagnosis of 5 years, and fasting C-peptide of 0.65 ng/ml.

Conclusions

Clinical, biochemical and genetic characteristics of patients with NIR-SPIDDM are different from those of IR-SPIDDM patients. Age of diabetes onset, duration before GADAb-positivity, GADAb level, and fasting C-peptide at diagnosis must be carefully considered in planning prevention trials for SPIDDM.

SUBMITTER: Yasui J 

PROVIDER: S-EPMC4866691 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical and Genetic Characteristics of Non-Insulin-Requiring Glutamic Acid Decarboxylase (GAD) Autoantibody-Positive Diabetes: A Nationwide Survey in Japan.

Yasui Junichi J   Kawasaki Eiji E   Tanaka Shoichiro S   Awata Takuya T   Ikegami Hiroshi H   Imagawa Akihisa A   Uchigata Yasuko Y   Osawa Haruhiko H   Kajio Hiroshi H   Kawabata Yumiko Y   Shimada Akira A   Takahashi Kazuma K   Yasuda Kazuki K   Yasuda Hisafumi H   Hanafusa Toshiaki T   Kobayashi Tetsuro T  

PloS one 20160513 5


<h4>Aims</h4>Glutamic acid decarboxylase autoantibodies (GADAb) differentiate slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) from phenotypic type 2 diabetes, but many GADAb-positive patients with diabetes do not progress to insulin-requiring diabetes. To characterize GADAb-positive patients with adult-onset diabetes who do not require insulin therapy for >5 years (NIR-SPIDDM), we conducted a nationwide cross-sectional survey in Japan.<h4>Methods</h4>We collected 82 GADA  ...[more]

Similar Datasets

| S-EPMC8936135 | biostudies-literature
| S-EPMC397475 | biostudies-literature
| S-EPMC6224891 | biostudies-literature
| S-EPMC3580128 | biostudies-literature
| S-EPMC10875177 | biostudies-literature
| S-EPMC6626941 | biostudies-literature
| S-EPMC4014934 | biostudies-literature
| S-EPMC4838033 | biostudies-literature
| S-EPMC10486372 | biostudies-literature